We are live on ! Find out more
EPIX

ESSA Pharma
EPIX

Delisted

EPIX was delisted on the 8th of October, 2025.

Back to rankings

8 hedge funds and large institutions have $13.1M invested in ESSA Pharma in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

26.19% more ownership

Funds ownership: 60.68% → 86.87% (+26%)

0% more capital invested

Capital invested by funds: $13.1M → $13.1M (+$28K)

0% more funds holding

Funds holding: 8 → 8 (0)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
3
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$2.23M
2
BI
BVF Inc
California
+$1.85M
3
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$7

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$269

EPIX Hedge Fund Activity: Q2 2019 in Review

8 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2019, worth a combined $13.1M — up 0.21% from $13.1M a quarter earlier.

Fund positioning in EPIX was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $2.23M. The largest seller was Royal Bank of Canada, cutting an estimated $269.

  • 8 institutional investors held ESSA Pharma (EPIX) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $13.1M of ESSA Pharma stock for Q2 2019, up 0.21% quarter-over-quarter.
  • 0 funds opened new ESSA Pharma positions in Q2 2019 and 0 closed out.
  • The largest ESSA Pharma buyer in Q2 2019 was Eventide Asset Management, an estimated $2.23M added.
  • The largest ESSA Pharma seller in Q2 2019 was Royal Bank of Canada, an estimated $269 sold.

Based on aggregated 13F filings for Q2 2019.